Genovate Biotechnology Past Earnings Performance
Past criteria checks 2/6
Genovate Biotechnology's earnings have been declining at an average annual rate of -36.8%, while the Pharmaceuticals industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 0.9% per year. Genovate Biotechnology's return on equity is 2%, and it has net margins of 5.6%.
Key information
-36.8%
Earnings growth rate
-36.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | 0.9% |
| Return on equity | 2.0% |
| Net Margin | 5.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Reflecting on Genovate Biotechnology's (GTSM:4130) Share Price Returns Over The Last Five Years
Mar 09
Does It Make Sense To Buy Genovate Biotechnology Co., Ltd. (GTSM:4130) For Its Yield?
Feb 10Genovate Biotechnology Co., Ltd.'s (GTSM:4130) Dismal Stock Performance Reflects Weak Fundamentals
Jan 04
How Much Did Genovate Biotechnology's(GTSM:4130) Shareholders Earn From Share Price Movements Over The Last Five Years?
Dec 08Revenue & Expenses BreakdownBeta
How Genovate Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 529 | 29 | 110 | 74 |
| 30 Sep 23 | 524 | 30 | 110 | 70 |
| 30 Jun 23 | 503 | 21 | 108 | 71 |
| 31 Mar 23 | 471 | 10 | 105 | 63 |
| 31 Dec 22 | 439 | -12 | 107 | 62 |
| 30 Sep 22 | 436 | 3 | 57 | 49 |
| 30 Jun 22 | 439 | -12 | 100 | 59 |
| 31 Mar 22 | 430 | -18 | 99 | 58 |
| 31 Dec 21 | 434 | 0 | 95 | 55 |
| 30 Sep 21 | 413 | -10 | 95 | 57 |
| 30 Jun 21 | 417 | 12 | 96 | 49 |
| 31 Mar 21 | 440 | 29 | 98 | 52 |
| 31 Dec 20 | 473 | 39 | 99 | 55 |
| 30 Sep 20 | 487 | 43 | 101 | 57 |
| 30 Jun 20 | 476 | 32 | 100 | 61 |
| 31 Mar 20 | 466 | 29 | 101 | 60 |
| 31 Dec 19 | 466 | 34 | 101 | 57 |
| 30 Sep 19 | 470 | 39 | 96 | 69 |
| 30 Jun 19 | 467 | 63 | 100 | 64 |
| 31 Mar 19 | 464 | 58 | 102 | 62 |
| 31 Dec 18 | 456 | 58 | 102 | 61 |
| 30 Sep 18 | 443 | 96 | 109 | 60 |
| 30 Jun 18 | 439 | 98 | 112 | 57 |
| 31 Mar 18 | 434 | 158 | 112 | 53 |
| 31 Dec 17 | 408 | 149 | 111 | 51 |
| 30 Sep 17 | 412 | 112 | 106 | 37 |
| 30 Jun 17 | 420 | 90 | 100 | 39 |
| 31 Mar 17 | 414 | 29 | 96 | 44 |
| 31 Dec 16 | 411 | 39 | 95 | 55 |
| 30 Sep 16 | 439 | 41 | 101 | 63 |
| 30 Jun 16 | 443 | 49 | 101 | 66 |
| 31 Mar 16 | 452 | 51 | 103 | 67 |
| 31 Dec 15 | 478 | 46 | 106 | 58 |
| 30 Sep 15 | 454 | 44 | 109 | 51 |
| 30 Jun 15 | 467 | 52 | 112 | 50 |
| 31 Mar 15 | 479 | 70 | 113 | 46 |
| 31 Dec 14 | 475 | 73 | 112 | 44 |
| 30 Sep 14 | 464 | 73 | 105 | 39 |
| 30 Jun 14 | 443 | 63 | 104 | 34 |
| 31 Mar 14 | 419 | 56 | 102 | 33 |
| 31 Dec 13 | 397 | 46 | 100 | 32 |
| 30 Sep 13 | 382 | 44 | 100 | 31 |
| 30 Jun 13 | 363 | 73 | 98 | 36 |
Quality Earnings: 4130 has high quality earnings.
Growing Profit Margin: 4130 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4130's earnings have declined by 36.8% per year over the past 5 years.
Accelerating Growth: 4130 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 4130 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-10.7%).
Return on Equity
High ROE: 4130's Return on Equity (2%) is considered low.